Rituparna Power Point Representation

8/12/2019 Rituparna Power Point Representation

1/25

RITUPARNA DAS

ROLL :99/05/PG-III

NO: 130035

3rd SEMESTER

Department of Chemistry

University of North Bengal


2/25

SOLID LIPID NANO PARTICLES:

Solid lipid nanoparticles (SLN) made from solid lipids are

attracting major attention as novel colloidal drug carrier for intravenous

applications as they have been proposed as an alternative particulate

carrier system. SLN are sub-micron colloidal carriers ranging from 50 to

1000 nm, which are composed of physiological lipid, dispersed in wateror in aqueous surfactant solution.

Fig.1:Structure of solid lipid nanoparticle


3/25

Fig.2:A diagrammatic representation on SLN overemulsions and liposomes


4/25

: Advantages of SLN :

Use of biodegradable physiological lipids which decreases the danger of acute and

chronic toxicity and avoidance of organic solvents in production methods .

Improved bioavailability of poorly water soluble molecules .

Site specific delivery of drugs, enhanced drug penetration into the skin via dermal

application .

Possibility of scaling up.

SLNs have better stability compared to liposomes .


5/25

Lyophilization possible

Much easier to manufacture than biopolymeric nanoparticles.

No special solvent required.

Raw materials essential the same as in emulsions.

Very high long-term stability.

Application versatility.

Can be subjected to commercial sterilization procedures.


6/25

: Disadvantages of SLN :

Poor drug loading capacity.

Drug expulsion after polymeric transition during storage .

Relatively high water content of the dispersions .

Particle growth.

Unpredictable gelation tendency.


7/25

Methods of Preparation:

1.High pressure homogenization

i. Hot homogenization

ii. Cold homogenization

2.Ultrasonication homogenization

3. Solvent evaporation method

4.Solvent emulsification-diffusion

method

5.Spray drying method

6.Supercritical Fluid technology

7.Microemulsion based method

8.Double emulsion method

9.Precipitation technique

10.Film-ultrasound dispersion


8/25

: Nanostructured lipid carriers (NLC) :

Nanostructured lipid carriers (NLC) are the second generation

SLN composed of solid lipid matrix which are incorporated with liquid lipids.

NLC with less organized crystalline structure and therefore provides better

loading capacity for drug accommodation. To overcome the stability and drug

expulsion problems of SLN, the NLC had emerged.

Fig.3:Electron microscopy picture of NLC


9/25

: Aims of solid lipid nanoparticles :

Possibility of controlled drug release.

Increased drug stability.

No bio-toxicity of the carrier.

: Materials used in SLN :

My system of SLN is Soya lecithin , Tripalmitine and Cetylpalmitate. The surfactant I used is Brij-35, a nonionic surfactant.


10/25

Fig4: Structural formula of

soyalecithine(C42H80NO8P)

Fig5: Structural formula of Cetyl

palmitate(C32H64O2)

Fig6:Structural formula of

tripalmitine(C51H98O6)

Fig7: Structural formula of Brij-35(C58H118O24)


11/25

: Reason for choosing this type of system:

There is Structural similarity between the components of mysystem. Brij-35 is easily biodegradable and non toxic as it is used as

my surfactant.

: Applications of SLN :

Solid lipid nanoparticles in Drug delivery:

Fig 13: Drug delivery By nanoparticles


12/25

Solid lipid nanoparticles in cancer chemotherapy:

Fig.14:A chemotherapy-f il led nanopart icle (lavender) i s coated with targeting molecules (blue-purple) that bind to cancer cell s. Once the

nanoparti cle is inside a cell , it releases the drugs (yell ow). [Ar t:

Nicolle Rager Full er]

SLN for Parenteral Application:

Cationic SLN has been demonstrated to bind genes directly via

electrostatic interactions, and have potential benefits in targeted gene

therapy in treatment of cancer.


13/25

Targeted delivery of solid lipid nanoparticles for the treatment of lung diseases:

Fig.15:Targeted deli very of solid li pid nanoparti cles for the treatment of l ung diseases


14/25

: Analytical characterization of SLN :

Measurement of particle size and zeta potential:

1.Dynamic light scattering (DLS):

DLS also known as PCS records the variation in the intensity of the

scattered light on the microsecond time scale.

Fig9:Intensity vs size diagram of Solid Lipid NanoParticles


15/25

2.Electron microscopy:

Fig 10:Elecronic microscopic image of Solid Lipid NanoParticles3.Atomic force microscopy (AFM):

Fig 11:AF M image of Solid lipid nanoparticles


16/25

: Plan of Work :The present work aims at the following:

To characterize the solid lipid nano particles.


17/25

: Experiment :

: Material : Lipid soylecithin, tripalmitine and cetyl palmitate

(SLC:TP) Wt% of CP SLC(mg) TP(mg) CP(mg) Total(mL)1:1 5% 7.2 7.6 0.5 201:1 10% 6.8 7.2 0.9 201:1 15% 6.4 6.8 1.4 201:1 20% 6.0 6.4 1.9 201:1 25% 5.6 6..0 2.4 201:1 30% 5.3 5.6 2.8 20

Table:1.Composition of System


18/25

: Result :1:1 SLC-TP and 5% CP 1:1 SLC-TP and 10% CP 1:1 SLC-TP and 15% CPTime/day Size/nm Time/day Size/nm Time/day Size/nm1 226.3 2 183.6 1 199.62 140.1 7 206.3 7 202.74 168.4 13 218.7 20 178.511 168.1 20 160.6 27 174.224 169 26 159 78 149.830 147.9 77 153.9 84 142.881 141.6 83 144.787 148.7

1:1 SLC-TP and 20% CP 1:1 SLC-TP and 25% CP 1:1 SLC-TP and 30% CPTime/day

Time/day

Time/day

Size/nm

Time/day

Size/nm

2 229.9 1 215.5 4 179.68 190.2 7 196.4 5 181.415 182.1 14 176.5 12 173.821 186.1 20 179.4 18 167.672 173.4 71 146.1 69 159.778 172.8 77 138.2 75 151.3

Table2: Variation in the hydrodynamic diameter of SLN at different time intervals.


19/25

0 20 40 60 80 100

140

160

180

200

220

240

260

size/nm

time/day

CP 5%

CP 10%

CP 15%CP 20%

CP 25%

CP 30%

Graph1:Variation in the hydrodynamic diameter of SLN at different time intervals.


20/25

Wt % of CP Zeta Potential5 -5.7210 -12.115 -4.8420 -13.525 -9.0830 -16.7

Table3: Variation in the Zeta Potential of SLN with varying concentration of Wt % of CP:

5 10 15 20 25 30

-18

-16

-14

-12

-10

-8

-6

-4

Zetapotential/mv

wt % of CP

zeta potential

Graph2:Variation in the Zeta Potential of SLN at different Wt% of CP


21/25

: Conclusion :

From the graph 1 the solution containing 20%

wt of CP is quite stable. It take 20 days to reach

equllibrating position . Others show much fluctuation .

There is a net decrease of Zeta potential value

with increasing concentration of CetylPalmitate(Graph:2)

. Results are further evidenced through above Figure


22/25

-:FUTURE PROSPECTIVE:-However, to draw final conclusion on this

aspect, further studies using varios

combination of lipids are warranted.This can be considered as the future

perspective.


23/25

: Acknowledgment:

I wish to express my sincere thanks and gratitude to myteacher Dr. A.K. Panda for his immensely valuable guidance

and suggestions to complete this work. My thanks and

appreciation also goes to all the faculty members of the

Department of Chemistry, University of North Bengal fortheir help and encouragement.

I am also thankful to the research fellows Gourab

Karmakar,Prasant Nahak, Manish Sapkota, Biplab , BanitaSinha, Moumita Chakraborty, Pritam Guha and my friends

for their constant support and encouragement in every

step.during this project work.


24/25

:References:

1. Coleman Anthony W., Jebors Said, et al. (2008). "para-Acylcalix[n]arenes: from molecular to

macroscopic assemblies." Chem. Commun.

2. DA SILVA ADRIANA L. , SANTOS RAQUEL S. , et al. (2012). "Nanoparticle-based therapy for

respiratory diseases." An. Acad. Bras. Cinc 85.

3. EKAMBARAM. P, S. A. A. HASAN, et al. (2012). "SOLID LIPID NANOPARTICLES: A REVIEW."

Sci. Revs. Chem. Commun 2(1): 80-102.

4. Gambhire Makarand Suresh , Bhalekar Mangesh Ramesh , et al. "Statistical optimization of dithranol-

loaded solid lipid nanoparticles using factorial design." Brazilian Journal of Pharmaceutical Sciences 47.

5. Garud Akanksha, Singh Deepti, et al. (2012). "Solid Lipid Nanoparticles (SLN): Method,

Characterization and Applications." International Current Pharmaceutical Journal 1(11): 384-393.

6. EH, Korkmaz E, et al. (2012). "Resveratrol-loaded solid lipid nanoparticles versus nanostructured lipid

carriers: evaluation of antioxidant potential for dermal applications." Int J Nanomedicine

7. Sahu MK, Soni GC, et al. (2012). "Nanostructured Lipid Carrier: The Second Generation of Solid Lipid

Nanoparticle." International Journal for Pharmaceutical Research Scholars (IJPRS) 1(3).

8. Singhal Girish B., Patel Rakesh P., et al. (2011). "SOLID LIPID NANO PARTICLES AND NANO

LIPID CARRIERS: AS NOVEL SOLID LIPID BASED DRUG CARRIER." International Reseach Journal

Of Pharmacy 2(2): 40-52.

9. Wissinga S.A., Kayserb O. , et al. (2003). "Solid lipid nanoparticles for parenteral drug delivery."

Advanced Drug Delivery Reviews: 1257-1272.


25/25

THANK YOU

Documents

Rituparna Power Point Representation